Pioglitazone, a PPAR-y agonist, as one of the new therapeutic candidates for C3 glomerulopathy.

[1]  M. Hattori,et al.  Pioglitazone enhances proteinuria reduction in complicated pediatric nephrotic syndrome , 2022, Pediatric Nephrology.

[2]  B. Rovin,et al.  KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. , 2021, Kidney international.

[3]  J. Thurman,et al.  A clinical approach to children with C3 glomerulopathy , 2021, Pediatric Nephrology.

[4]  T. Cavero,et al.  Update on C3 Glomerulopathy: A Complement-Mediated Disease , 2020, Nephron.

[5]  L. Greenbaum,et al.  Nephrotic Syndrome. , 2019, Pediatric clinics of North America.

[6]  G. Remuzzi,et al.  C3 glomerulopathy — understanding a rare complement-driven renal disease , 2019, Nature Reviews Nephrology.

[7]  S. Agrawal,et al.  Pioglitazone Enhances the Beneficial Effects of Glucocorticoids in Experimental Nephrotic Syndrome , 2016, Scientific Reports.

[8]  R. Fukuzawa,et al.  Membranoproliferative glomerulonephritis and C3 glomerulonephritis: Frequency, clinical features, and outcome in children , 2015, Nephrology.

[9]  P. Sarafidis,et al.  Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: a meta-analysis. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[10]  B. Ranchin,et al.  Disease recurrence in paediatric renal transplantation , 2009, Pediatric Nephrology.

[11]  P. Kincaid‐smith,et al.  Reduction of proteinuria by rosiglitazone in non‐diabetic renal disease , 2007, Nephrology.

[12]  A. Pozzi,et al.  PPAR-γ agonist protects podocytes from injury , 2007 .